Tumor eradication by adoptive transfer of cytotoxic T lymphocytes.
about
T cell receptor-like recognition of tumor in vivo by synthetic antibody fragmentRole of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity.Induction of a polarized Th1 response by insertion of multiple copies of a viral T-cell epitope into adenylate cyclase of Bordetella pertussis.Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cellsDelivery of multiple epitopes by recombinant detoxified adenylate cyclase of Bordetella pertussis induces protective antiviral immunity.Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors.Principles of adoptive T cell cancer therapy.Construction, purification, and functional incorporation on tumor cells of glycolipid-anchored human B7-1 (CD80).Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans.Development of an MHC class I L(d)-restricted PSA peptide-loaded tetramer for detection of PSA-specific CD8+ T cells in the mouse.Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopesCytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cellsCD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses.Intratumoral immunotherapy: using the tumour against itself.Phase 1 Clinical Trial of Trametes versicolor in Women with Breast CancerAnti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humansCombining radiotherapy and immunotherapy: a revived partnership.Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity.Identification of a unique antigen peptide pRL1 on BALB/c RL male 1 leukemia recognized by cytotoxic T lymphocytes and its relation to the Akt oncogene.A reassessment of the role of B7-1 expression in tumor rejection.Decreased tumor surveillance in perforin-deficient mice.Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein.Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes.Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes.Antigen-coated poly α-hydroxy acid based microparticles for heterologous prime-boost adenovirus based vaccinationsSpontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide.Induction of cytotoxic T-lymphocytes and antitumor activity by a liposomal lipopeptide vaccine.Post-transplant adoptive T-cell immunotherapy.Key role for neutrophils in radiation-induced antitumor immune responses: Potentiation with G-CSF.Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction.Chimeric antigen receptors: driving immunology towards synthetic biology.Adoptively transferred human lung tumor specific cytotoxic T cells can control autologous tumor growth and shape tumor phenotype in a SCID mouse xenograft model.Therapeutic T cell engineering.ICAM-1 (intercellular adhesion molecule-1) gene transfection inhibits lymph node metastasis by human gastric cancer cells.Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma.CD4 T cells and their role in antitumor immune responses.Rational design of Polymeric Hybrid Micelles to Overcome Lymphatic and Intracellular Delivery Barriers in Cancer Immunotherapy.Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy.Augmented induction of CD8+ cytotoxic T-cell response and antitumour resistance by T helper type 1-inducing peptide.Tumour necrosis factor-alpha (TNF-alpha) transgene-expressing dendritic cells (DCs) undergo augmented cellular maturation and induce more robust T-cell activation and anti-tumour immunity than DCs generated in recombinant TNF-alpha
P2860
Q27322455-7BCBC17A-EBC9-4E93-82E0-7B72C92F350DQ30769959-6C386C7C-D804-4AE8-B57C-F4A6AEDC4761Q33595975-FC4A4ED9-3A92-4A7D-8A3F-62C087852313Q33848587-A292AECD-D0E0-421D-8BE7-B4D2ECBEC656Q33852549-BA491697-E87B-44F8-AE1F-CDC9E2B534F5Q33944674-C3AD652F-B92A-4079-AB50-42C65D10FB30Q34003932-56BF333D-8C50-4836-9898-AD6B1336C6A2Q34027192-869318F3-19BE-4601-9ED5-A0B7AC2D3CEBQ34195888-5FF050A3-D127-4857-9D9E-ED5C4D94F347Q34981174-805C9AAC-628F-4083-8E86-C2CA5E17011BQ35093159-18497DBA-A0A0-4D5D-AB66-455E993FDFD9Q35227334-59D65B3A-425D-4B60-9D1B-745B01A45162Q35978636-10069548-A376-4087-BFD7-F7FA13749E74Q35988030-0560E268-2FE8-4E22-81C0-38154C8E1ED4Q36014565-A24AD6DD-8213-4AF9-9A8A-FAFF87BA7139Q36239694-21F41962-589A-4E41-A761-C444A7169BC7Q36274581-585DA34F-EADB-473E-9B73-AD52E985EBD7Q36362788-5A3F1029-7229-48A8-8E6C-1F965ABA46DFQ36363927-945F37BE-EF23-44A0-9789-E7BC5856F1ADQ36365375-E9AFA825-4624-496A-969C-B2A037779915Q36367528-09A82163-D55F-4B15-9E7F-093B99F3B542Q36375409-0E3828B7-CDA5-495D-B8AE-1FC5EE282218Q36380515-A83F0587-96EA-49E4-B1CC-86D7B3CF2885Q36404076-AE875B36-A19D-46F7-A2BC-CCDB850EBB9CQ36569221-FF1F499E-6AA3-43B9-8921-385BA66E3736Q37049451-58BF8292-BE47-4748-84D3-6EDCE28932F8Q37213029-B53E7FE1-0473-4091-ABF8-5979BE50DD01Q37268318-D15AE416-54D1-4400-AA79-28B094CC20FAQ37322905-CE42A8F1-D778-4D34-9C70-29CD31F5DF6AQ37445352-BA408A0F-BC50-4A5C-8BFD-08EC490B88E5Q38884383-3A155375-807A-4ED4-920F-E3CD385563DDQ40115182-564ACC9A-7F04-4342-9864-25051EBAB397Q40199809-85CBF19F-6138-4EB8-8DF0-7BBE203741F8Q40852058-C3DC9B0B-F6BF-449A-835E-9F3D9B081454Q40898769-C722C413-96EE-4BC7-A3C7-8B64C6954A0EQ41812728-4FF68205-4627-4CE9-B2DC-053F9BFEE135Q47099068-E7C62DAD-16E0-45DF-BB83-E5AB87C309DCQ52647752-73840BCE-4810-4026-9E95-21D71AD1094AQ53640046-0A46DA32-21E1-47A3-BC14-A558D0061948Q58862665-BBBD8134-227B-4806-832C-E0931A3F1BB9
P2860
Tumor eradication by adoptive transfer of cytotoxic T lymphocytes.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Tumor eradication by adoptive transfer of cytotoxic T lymphocytes.
@ast
Tumor eradication by adoptive transfer of cytotoxic T lymphocytes.
@en
type
label
Tumor eradication by adoptive transfer of cytotoxic T lymphocytes.
@ast
Tumor eradication by adoptive transfer of cytotoxic T lymphocytes.
@en
prefLabel
Tumor eradication by adoptive transfer of cytotoxic T lymphocytes.
@ast
Tumor eradication by adoptive transfer of cytotoxic T lymphocytes.
@en
P1476
Tumor eradication by adoptive transfer of cytotoxic T lymphocytes.
@en
P2093
P304
P577
1992-01-01T00:00:00Z